Adam D’Augelli is a Partner at True Ventures, a leading early-stage venture capital firm founded in 2005. With a foundational mission to empower entrepreneurs at the initial stages of company creation, True has partnered with over 1,050 Founders across more than 500 companies. The firm’s 12 funds have been a part of seven IPOs and over 60 acquisitions.Adam joined True as an analyst in 2010, immediately after graduating magna cum laude from the University of Florida with a bachelor’s degree in science and a master’s degree in finance. Adam currently serves on the NVCA’s Board of Directors. Adam has led True’s investments in Splice, Pendulum Therapeutics, Deep Genomics, Kettle, Radiant Graph, Dinamo Bio, The Nuclear Company, SuppCo, Howie, and others currently in stealth. His notable past investments include HashiCorp (NASDAQ: HCP), TripleLift (acquired by Vista Equity), Ring (acquired by Amazon), Runscope (acquired by CA Technologies), and Moleculo (acquired by Illumina).Topics:

The State of the Seed Market 2025: Why this is the best—and hardest—time to be a seed investor

Abundance vs. Scarcity: How compounding innovation across AI, biotech, and blockchain is reshaping early-stage opportunity

Building for the Next 30 Years: Why the future of venture belongs to investors with clear differentiation and conviction

#VentureCapital #SeedStage #TrueVentures #FrontierTech #AIInnovation

Adam D’Augelli, True Ventures Partner on Backing Founders from Day One

Venture with Grace